TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31553474

Group type: COMPARATOR
Intervention: Randomized control trial (uninformative visits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EHR data (potentially informative visits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EHR data with some uninformative visits
Number of subjects: 0
Study: 28153768

Group type: EXPERIMENTAL
Intervention: PABC intervention (Months 1-3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No physical activity intervention (attention control, Months 1-3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No contact (intervention wash-out, Months 4-6)
Number of subjects: 32
Study: 25986699

Group type: EXPERIMENTAL
Intervention: Enhancing Parenting Skills (EPaS) 2014 programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list treatment as usual control group
Number of subjects: 60
Study: 24183218

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5%
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Topical adenosine 0.75%
Number of subjects: 110
Study: 21810107

Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretation
Number of subjects: 100
Study: 20024680

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/valsartan 320 mg/hydrochlorothiazide 25 mg (triple therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Valsartan 320 mg/hydrochlorothiazide 25 mg (dual therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg/valsartan 320 mg (dual therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine 10 mg/hydrochlorothiazide 25 mg (dual therapy)
Number of subjects: 0
Study: 17219991

Group type: EXPERIMENTAL
Intervention: Survivin expression in differentiated thyroid carcinomas
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: VEGF expression in differentiated thyroid carcinomas
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Correlation of Survivin with VEGF and MVD
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Clinical stages, tumor complete capsule, and lymph node metastasis
Number of subjects: 67

Group type: COMPARATOR
Intervention: Survivin expression in thyroid adenoma and normal thyroid tissues
Number of subjects: 67
Study: 12963991

Group type: EXPERIMENTAL
Intervention: Tegafur suppositories (750 mg/day) from 1 to 2 weeks prior to surgery, to 2 weeks following surgery, followed by oral administration of tegafur and uracil (UFT) (260 mg/m(2)) for 1 year
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFT (260 mg/m(2)) for 1 year beginning week 2 after surgery
Number of subjects: 0
Study: 10934462

Group type: EXPERIMENTAL
Intervention: Reported history of cataract at baseline
Number of subjects: 18669

Group type: COMPARATOR
Intervention: Men without reported cataract
Number of subjects: 18669
Study: 8750446

Group type: EXPERIMENTAL
Intervention: Consent form provided at least 24 hours prior to procedure
Number of subjects: 160

Group type: COMPARATOR
Intervention: Consent form provided at the time of the procedure
Number of subjects: 160
Study: 1574257

Group type: EXPERIMENTAL
Intervention: Estrogen receptor assay performed at the largest cross-section of a large tumor
Number of subjects: 35

Group type: COMPARATOR
Intervention: Estrogen receptor assay performed on a small random part of a large tumor
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Multiple assays of ER levels in tumors
Number of subjects: 35
Study: 4081525

Group type: EXPERIMENTAL
Intervention: Interferon nasal spray (IFN-alpha), 50,000 IU per day, sprayed twice a day.
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo group (control).
Number of subjects: 73
Study: 30549143

Group type: EXPERIMENTAL
Intervention: Total Sleep Time (TST)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 41
Study: 29234869

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 27541801

Group type: EXPERIMENTAL
Intervention: Intravenous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration
Number of subjects: 12
Study: 24326003

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg/day
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 22019270

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 562

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 562
Study: 21313927

Group type: EXPERIMENTAL
Intervention: Preoperative biomarkers (Cardiac Troponin T, N-Terminal pro-Brain Natriuretic Peptide, high sensitivity C-Reactive Protein, blood glucose)
Number of subjects: 1731

Group type: COMPARATOR
Intervention: NNE preoperative risk prediction model without biomarkers
Number of subjects: 1731
Study: 17661239

Group type: EXPERIMENTAL
Intervention: C-Flex mode (level 2) for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: fix CPAP for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: C-Flex mode
Number of subjects: 20

Group type: COMPARATOR
Intervention: fix CPAP
Number of subjects: 20
Study: 16261288

Group type: EXPERIMENTAL
Intervention: Thrombolytic regimen with half reteplase (r-PA) dose plus abciximab
Number of subjects: 38

Group type: COMPARATOR
Intervention: Full dose r-PA
Number of subjects: 38
Study: 12239969

Group type: EXPERIMENTAL
Intervention: Billroth I (BI)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Billroth II (BII)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Roux-en-Y (Roux)
Number of subjects: 45
Study: 10391812

Group type: EXPERIMENTAL
Intervention: Relatives of persons with type 2 diabetes
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 8699540

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment interventions (4-month duration)
Number of subjects: 184
Study: 1852400

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable (RGP) lenses worn overnight
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no lens) condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 h closed-eye condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Soft lens types worn overnight
Number of subjects: 12
Study: 6299329

Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 0
Study: 29794108

Group type: EXPERIMENTAL
Intervention: Airway clearance physiotherapy (ACT) prior to cardiopulmonary exercise testing (CPET)
Number of subjects: 12
Study: 28199679

Group type: EXPERIMENTAL
Intervention: DNA/rAd5 vaccine
Number of subjects: 2504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2504
Study: 25733243

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg PO
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: S‐methyl‐l‐thiocitrulline (SMTC, 0.05, 0.1, and 0.2 μmol/min)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (hypertensive subjects)
Number of subjects: 88
Study: 24455682

Group type: EXPERIMENTAL
Intervention: Triptolide (1 mg/kg · d) combined with prednisone (2 mg/kg · d) for 6 to 9 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 56
Study: 21165798

Group type: EXPERIMENTAL
Intervention: Occlusion (OCC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study: 19055184

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16579250

Group type: EXPERIMENTAL
Intervention: Postoperative physical training (muscular strength and work capacity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control (relaxation exercises, hot wrappings, and massage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative physical training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 15101027

Group type: EXPERIMENTAL
Intervention: Combined salbutamol and ipratropium bromide
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nebulized saline (placebo)
Number of subjects: 22
Study: 10694120

Group type: EXPERIMENTAL
Intervention: Creatine (CR) loading (20 g x d(‐1) for 5 days)
Number of subjects: 14
Study: 9060898

Group type: EXPERIMENTAL
Intervention: 79% helium/21% oxygen mixture (He)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 15
Study: 8112803

Group type: EXPERIMENTAL
Intervention: 200 mg zinc sulphate (elemental Zn 45 mg) orally/day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (untreated group of 62)
Number of subjects: 106
Study: 3533088

Group type: EXPERIMENTAL
Intervention: Spleen dialysate Solcosplen (2 ampoules i.m. t.i.d. for 1 week, followed by 2 dragees b.i.d. for 7 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 2461017

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Logiparin) 35 XaI mu/kg b.w. once daily for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 100
Study: 31564231

Group type: EXPERIMENTAL
Intervention: 0.40 mg/kg tenecteplase (max 40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.25 mg/kg tenecteplase (max 25 mg)
Number of subjects: 0
Study: 29174779

Group type: EXPERIMENTAL
Intervention: High external suction (‐20 cm H2O)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Low external suction (‐5 cm H2O)
Number of subjects: 106
Study: 25740743

Group type: EXPERIMENTAL
Intervention: Oil-rich meals
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional low-oil meals
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 23916618

Group type: EXPERIMENTAL
Intervention: Mediolateral (ML) translations of the walking surface
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Gait adaptability task
Number of subjects: 19
Study: 21090875

Group type: EXPERIMENTAL
Intervention: ODD dimension of hurtfulness
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: ODD dimension of irritability
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Pretreatment ADHD
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Callous-unemotional (CU) traits
Number of subjects: 177
Study: 18438559

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% NaOCl+17% EDTA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epiphany
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study: 16989200

Group type: EXPERIMENTAL
Intervention: Local cutaneous alpha therapy with radon applicator (7.4 Bq/l, 90 minutes)
Number of subjects: 42

Group type: COMPARATOR
Intervention: EHF (460 MHz) electromagnetic field
Number of subjects: 42
Study: 15558381

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Constraint-Induced Therapy (CIT)
Number of subjects: 20
Study: 11401128

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) three times a week for six months at 60% of peak VO2
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 118
Study: 9029747

Group type: EXPERIMENTAL
Intervention: Albendazole alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Albendazole with dexamethasone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Albendazole with dexamethasone and cimetidine
Number of subjects: 24
Study: 8117358

Group type: EXPERIMENTAL
Intervention: 32 g sugar‐beet fibre/d
Number of subjects: 9
Study: 3494725

Group type: EXPERIMENTAL
Intervention: Metronidazole (2 g single dose)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Nimorazole (2 g single dose)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 280
Study: 30197317

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transrectal ultrasound (CETRUS)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Transrectal ultrasonography (TRUS)
Number of subjects: 207
Study: 27635617

Group type: EXPERIMENTAL
Intervention: Pantogam syrup 10% (hopantenic acid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Psychological methods (Control group)
Number of subjects: 60
Study: 25055492

Group type: COMPARATOR
Intervention: General anaesthesia (Group C)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Combined general‐epidural anaesthesia (Group CA)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: General anaesthesia with Droperidolum (Group D)
Number of subjects: 127
Study: 22416791

Group type: EXPERIMENTAL
Intervention: Promotora-taught cancer screening/prevention classes delivered individually (IND)
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Promotora-taught cancer screening/prevention classes delivered in social support groups (SSG)
Number of subjects: 1006
Study: 20579955

Group type: EXPERIMENTAL
Intervention: Betamethasone administered in a randomized controlled trial of weekly antenatal corticosteroids (ACS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (nonobese women)
Number of subjects: 100
Study: 17943385

Group type: EXPERIMENTAL
Intervention: CO(2) pneumoperitoneum (CO(2)PP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparolift (abdominal wall elevator)
Number of subjects: 20
Study: 15946117

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 25
Study: 12889565

Group type: EXPERIMENTAL
Intervention: Percutaneous acetic acid injection (PAI) using 50% acetic acid
Number of subjects: 125

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI) using pure ethanol
Number of subjects: 125
Study: 10967901

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load (10 cmH2O/L/sec) during quiet breathing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load during hypercapnic stimulation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Inspiratory resistive load during loaded breathing
Number of subjects: 23

Group type: COMPARATOR
Intervention: Inspiratory resistive load during hypoxic stimulation
Number of subjects: 23
Study: 9234616

Group type: EXPERIMENTAL
Intervention: Combined therapy with ciprofloxacin (CPFX) and clarithromycin (CAM), 600 mg/day for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single therapy with ciprofloxacin (CPFX), 600 mg/day for 14 days
Number of subjects: 0
Study: 7690225

Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride (hypertonic saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride combined with 6% dextran 70
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride combined with 12% dextran 70
Number of subjects: 0
Study: 2871742

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 31127779

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) targeting the right dorsolateral prefrontal cortex, 10 sessions
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 21
Study: 28007405

Group type: EXPERIMENTAL
Intervention: Ephedrine 50 mg daily in 2 doses
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 25999694

Group type: EXPERIMENTAL
Intervention: SYP‐1018 (200 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vfend(®) (200 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SYP‐1018 and Vfend(®)
Number of subjects: 52
Study: 23758690

Group type: EXPERIMENTAL
Intervention: Specially developed training programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual methods of implementation and training
Number of subjects: 40
Study: 22038637

Group type: EXPERIMENTAL
Intervention: Prophylactic IABP insertion (group B, n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No prophylactic IABP insertion (group A, n=52)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Prophylactic IABP insertion (group B)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No prophylactic IABP insertion (group A)
Number of subjects: 104
Study: 19508963

Group type: EXPERIMENTAL
Intervention: Regular aiming strategy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Different control strategy applied by experts
Number of subjects: 2

Group type: COMPARATOR
Intervention: Novice aiming strategy
Number of subjects: 2
Study: 17131250

Group type: EXPERIMENTAL
Intervention: Proview self-tonometer
Number of subjects: 150

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 150
Study: 15527607

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises and manometric biofeedback
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lifestyle changes (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 55
Study: 11419612

Group type: EXPERIMENTAL
Intervention: High responsibility condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low responsibility condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No responsibility condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responsibility manipulation
Number of subjects: 0
Study: 9576319

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 146

Group type: COMPARATOR
Intervention: Mock adjustment
Number of subjects: 146
Study: 7935028

Group type: EXPERIMENTAL
Intervention: Low dose hormone replacement (0.3 mg/day equine estrogen and 2.5 mg/day medroxyprogesterone)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Moderate dose hormone replacement (0.625 mg/day equine estrogen, days 1‐25, and 5 mg/day medroxyprogesterone, days 16‐25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Calcium only (control group)
Number of subjects: 75
Study: 3284690

Group type: EXPERIMENTAL
Intervention: Combination therapy (prazosin 2 mg b.i.d. and verapamil 160 mg b.i.d.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single drug treatment (prazosin or verapamil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29611086

Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV) 1g daily for 3 months with conventional treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with regular treatment only
Number of subjects: 100
Study: 28214091

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 25204719

Group type: EXPERIMENTAL
Intervention: Dark roast coffee (rich in N‐methylpyridinium)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Medium roast coffee (rich in caffeoylquinic acids, trigonelline)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study: 23425539

Group type: EXPERIMENTAL
Intervention: Primary PCI with bivalirudin
Number of subjects: 3602
Study: 21934625

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg per day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19784722

Group type: EXPERIMENTAL
Intervention: Karayahesive hydrocolloid dressing
Number of subjects: 253

Group type: COMPARATOR
Intervention: Tegaderm plus Pad polyurethane foam dressing
Number of subjects: 253
Study: 17010231

Group type: COMPARATOR
Intervention: Diet C (increased consumption of breakfast cereals)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Diet V (increased consumption of vegetables)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 67
Study: 15592786

Group type: EXPERIMENTAL
Intervention: 0.1% bromfenac sodium (Bromfenac)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.1% pemirolast potassium (Pemirolast)
Number of subjects: 22
Study: 11122840

Group type: EXPERIMENTAL
Intervention: Standard and high-dose chemotherapy
Number of subjects: 0
Study: 9132724

Group type: EXPERIMENTAL
Intervention: Random practice schedule
Number of subjects: 19

Group type: COMPARATOR
Intervention: Blocked practice schedule
Number of subjects: 19
Study: 7617628

Group type: EXPERIMENTAL
Intervention: Tactivin
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (Tactivin + antibacterial drugs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Antibacterial drugs alone (Control)
Number of subjects: 49
Study: 2929485

Group type: EXPERIMENTAL
Intervention: Animal protein (AP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Plant protein (PP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Animal protein (AP) diet
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Plant protein (PP) diet
Number of subjects: 8
Study: 323074

Group type: EXPERIMENTAL
Intervention: Lowest dose of norgestrel-ethinyl estradiol (20 microng estrogen, 100 microng progestogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of norgestrel-ethinyl estradiol (20 microng estrogen, increased progestogen in 100-microng increments)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of norgestrel-ethinyl estradiol
Number of subjects: 0
Study: 31047803

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg) administered intravenously once every 3 weeks.
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg).
Number of subjects: 115
Study: 27364549

Group type: EXPERIMENTAL
Intervention: Carvedilol 5mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Carvedilol 10mg (dose-escalation)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Carvedilol 20mg (dose-escalation)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Carvedilol 5mg, 10mg, 20mg
Number of subjects: 127